CD274 and neoplasm: In this review, we endeavor to describe the TME in NSCLC before and after treatment with TKIs from the following three perspectives: the tumor-infiltrating immune cells; immune checkpoints expressed by tumor and immune cells, such as PD-L1; and cytokines or chemokines.